A 52 week high and a $1 share price have seen a stellar run in the last 15 months.
CEO Scott Richards said the acquisition of Matrix is the game changer for MYX.
MYX have also been very busy with additional acquisitions and FDA approvals on its generic products such as
Kapanol
New 200mg Doryx Tablet
Libertas
Signs European SUBACAP Distribution
US agreement for Itraconazole in Cancer
LORCET & ESGIC.
The market is also liking what they see and oversubscribed in the last placement which also is a good sign of confidence going forward.
There is plenty of reasons to hold MYX and with many more generic products to come on line once they meet FDA approval should see further growth over the short to medium term.
Cheers Matsim
A 52 week high and a $1 share price have seen a stellar run in...
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.48 |
Change
0.000(0.00%) |
Mkt cap ! $381.1M | |||
| Open | High | Low | Value | Volume |
| $4.46 | $4.48 | $4.37 | $1.253M | 283.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 152 | $4.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.48 | 1042 | 2 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |